The healthcare sector has long been regarded as a defensive haven for investors seeking stability during periods of broader market turbulence and economic uncertainty. Low volatility stocks within healthcare tend to attract
MoreThe Class Three Lapis Lazuli Handicap at Sha Tin shapes up as the most difficult puzzle on the card, but finding the winner should pay rich dividends. Andrea Atzeni’s ultra-consistent Enthusium and
MoreRacing returns to Sha Tin on Sunday with an 11-race programme that includes two Group Three contests to close out the season. The week brought heavy disruption to Hong Kong, with 70
MoreThe 2026 FIFA World Cup is underway across North America, with matches being held in 16 cities spread across the United States, Canada, and Mexico. This marks only the second time in
MoreLegal professionals increasingly rely on AI tools to polish their resumes, but a recent experiment suggests the technology may not treat all lawyers equally. A thread by Jen Horsburgh described her experience
MoreBritish stocks are frequently overlooked by investors drawn to high-profile American names, but domestic equities have quietly delivered impressive returns. There are currently 42 members of the FTSE 100 that have outperformed
MoreMarkets advanced on Wednesday as semiconductor stocks led equity indices higher, while oil prices gained ground on growing doubts surrounding a potential Iran nuclear agreement. Chipmaker shares provided the primary engine of
MoreThe projected economic benefit of Heathrow’s third runway has been dramatically reduced, with new government analysis finding the expansion may boost GDP by just 0.05 per cent. That figure represents a 90
MoreThe UK’s pubs, hotels and restaurants are warning they face collapse under the weight of rising costs and what they describe as being “catastrophically overtaxed.” Higher business rates, national insurance hikes, minimum
MoreuniQure’s gene therapy AMT-130 has been given a renewed shot at regulatory approval after the FDA dramatically reversed its earlier position on the Huntington’s disease treatment. The agency now agrees that uniQure’s
More
